ANTIBODY THERAPEUTICS XCHANGE
EAST COAST 2023
Boston
May 22, 2023

Welcome to hubXchange’s Antibody Therapeutics Xchange East Coast 2023, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics, through a series of roundtable discussions.

Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-Specifics and Emerging Technologies.

Take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers.

Please note this is an In-Person meeting.

VENUE DETAILS: Hilton Boston Woburn Hotel, 2 Forbes Road, Woburn MA 01801

SNAPSHOTS OF DISCUSSION TOPICS

Track 1: Target Selection

Considerations and challenges guiding target selection in the development of antibody-based therapeutics for cancer
Selecting target pairs for bispecific therapeutic antibody development
Strategies and considerations of discovering antibodies against novel targets

Track 2: Lead Identification & Optimization

Challenging targets: Opportunity, vs effort, vs risk: General strategies vs custom approaches: In the end you want the best antibody, no matter what
One size doesn’t fit all: Key considerations for successful therapeutic antibody discovery for various modalities and indications.
Can NGS data from antibody screening be used to identify rare and high-affinity clones using machine learning?

Track 3: Formats & Scaffolds

Fc engineering for improved antibody druggability
Considerations for CAR-T/CAR-NK Cell binder format designs during screening and selections
Current Challenges in design of bispecific /chimeric antigen receptors for solid tumors

Track 4: Bi/Multi-Specifics

Bi/tri-specific strategies for overcoming cell engager toxicity

Track 5: Emerging Technologies

What is the optimum human CDR-H3 repertoire for antibody discovery?
Mining antibody repertoire from tumor patients

Full Xchange Agenda

Click on each track for detailed agenda

Target Selection

Time

Titles and Bullets

Facilitator

08:00 – 08:30

Registration

08:30 – 09:00

Opening Address & Keynote Presentation
Evolution of In Vivo Platforms for Antibody Drug Discovery

Ninety percent of the mAbs currently approved in the United States originated from immunized wild-type or human immunoglobulin (Ig) transgenic animals. Since the introduction of hybridoma technology in 1975, ongoing paradigm-shifting advances in novel technology platforms and antibody discovery methods have improved speed and efficiency, and overcome technical challenges. As a result, in vivo platforms continue to offer for the foreseeable future the widest applicability and most risk-mitigated path for successful antibody drug discovery and development. This talk will feature insights from AlivaMab Discovery Services and Ablexis, from our position as leaders in the discovery of superior antibody-based therapeutics for dozens of partners and with over a century of cumulative experience and success in the field.

Jane Seagal

Vice President, Antibody Discovery, Alivamab

Jane received her PhD from Technion-Israel Institute of Technology and completed her post-doctoral training at Harvard Medical School. She has over a decade of experience in antibody discovery for biologics drug development using in vivo approaches. Prior to joining AlivaMab Discovery Services, Jane led the In Vivo Antibody Discovery team at AbbVie, where she introduced and implemented multiple technology platforms, including hybridoma automation and direct antibody cloning from human patient samples. Jane has led projects across diverse therapeutic areas and enabled antibody discovery campaigns resulting in several clinical candidate molecules.

09:05 – 10:05

Considerations and challenges guiding target selection in the development of antibody-based therapeutics for cancer

What are the key criteria for selecting an antigen target? What specific considerations should be taken into account for tumor-associated antigens?
What are the pros and cons of targeting cell surface receptors vs. ligand targets? In the context of cancer, what are the pros and cons of targeting over-expressed self-antigens, cancer germline antigens, and neoantigens?
What impact, if any, does tumor type play in guiding target selection (i.e. liquid vs. solid tumors)?
What antibody parameters should be considered when selecting an antigen target? Antibody affinity? Epitope? Internalization rate? Other?
How does therapeutic modality influence target selection? (i.e. ADC, CAR-T, T-cell engager, conventional mAb)

Gadi Bornstein

Senior Director, External Innovation, Johnson & Johnson

Gadi Bornstein is a member of the External Innovation Team within Discovery, Product Development & Supply (DPDS) at the Johnson & Johnson Innovation Center in Boston. As a senior member of the global External Innovation Team, Gadi has overall strategic and operational responsibility for scouting and evaluation of external opportunities across all biologic drug modalities. Gadi has over twenty years of experience in oncology R&D with an emphasis in preclinical antibody discovery. He has led academic alliances as well as industry partnerships throughout his career. Prior to joining Janssen, Gadi was a Senior Director at TESARO, where he led and directed biologics discovery efforts in immuno-oncology. Before TESARO, Gadi held roles of increasing responsibility at Amgen Fremont Inc. (formerly Abgenix Inc.), AstraZeneca, Pfizer, and Novartis. Gadi received his B.S. in biochemistry from the University of California, Davis and his Ph.D. in biochemistry from the University of Southern California Keck School of Medicine. He completed his postdoctoral training at Stanford University in the Division of Immunology and Rheumatology. He has authored numerous research papers, reviews, as well as book chapters, and is a co-inventor on multiple patents.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning refreshments

11:20 – 12:20

Screening and discovery of novel nanobodies and their applications

What is the driving force for discovery of nanobodies compared to conventional antibodies?
What are the current methods for nanobody discovery and their advantages and limitations?
What is the current application and potential use of nanobodies in academic research, immunotherapy and clinical diagnostic imaging?
What can AlpalifeBio offer and deliver for our customers?

JinJun Gong

Chief Technology Officer, AlpalifeB

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation
Wrangling diverse OmniAb antibody repertoires with OmniDeep

We are presenting a showcase of discovering common light chain antibodies against a NK cell target. OmniDeep is a suite of in silico tools for antibody therapeutic discovery and optimization. Deep screening and high-throughput expression/characterization were used to seed information on top of NGS data sets. Our results demonstrate the power of this approach in corralling diverse OmniAb antibody repertoires and accelerating the development of effective therapeutics.

Bob Chen

Senior Director, Systems Engineering, OmniAb

Bob Chen is Senior Director of Systems Engineering at OmniAb. Dr. Chen leads the development of our xPloration® platform. Dr. Chen previously was the Chief Technology Officer and a co-Founder of xCella Biosciences, an antibody discovery and technology company based in Menlo Park, California, that was built on scientific research from Stanford University and MIT and acquired by Ligand Pharmaceuticals in 2020. Dr. Chen earned a Bachelor’s degree in Chemical Engineering from MIT and a PhD in Bioengineering from Stanford University.

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:00 – 15:30

Poster Session
Lead Identification & Optimization Topic
The future of developability profiling: AI-driven in silico immunogenicity screening and high throughput in vitro characterization

In silico immunogenicity and liability workflows leverage artificial neural networks to analyze proteins with unmatched throughput, speed, scalability, and accuracy.
Comprehensive and customizable in vitro characterization of physiochemical properties.
Combined in silico and in vitro output ranking benchmarked against >150 clinical mAbs

Shuji Sato

Senior Director of Client Relations – East Coast & Europe, ImmunoPrecise Antibodies

Shuji Sato holds a PhD from Tufts University in Massachusetts and completed his postdoctoral training at the New England Primate Research Center, Harvard Medical School. Prior to joining IPA, he worked for a variety of organizations in biotech and pharma, including Cell Signaling Technology and Pfizer, and most recently, he held the position of Associate Director, Antibody Discovery with Dragonfly Therapeutics.

15:35 – 16:35

Selecting target pairs for bispecific therapeutic antibody development

What are the key drivers for selection of target combinations?
Where are we most successful at identifying effective target combinations (e.g. specific class of MoAs, etc.)? Why are some more successful or easier than others?
What are some of the methods, data, assays being utilized for increasing the probability of success of selected target pairs? Can discovery of target pairs be industrialized?
How can ML/AI methods be applied for effective selection of target pairs?

Maria Wendt

Head of Biologics Research US & Global Head Digital Biologics Platform (ML/AI), Large Molecule Research, Sanofi

Maria Wendt is the Global Head of Digital Biologics and Biologics Strategy, Large Molecule Research Platform at Sanofi, based in Cambridge, MA. She has spent over 20 years at the interface of computation and biology. At Sanofi, she oversees the strategic innovation portfolio that ensures Sanofi is always in the forefront of molecular and computational innovations for biologics. She manages a global team in seven sites and five countries creating the next generation of smart biologics medicines using novel molecular engineering techniques, synthetic Biology and AI. She addresses novel biology for Immuno-oncology, Immunology, Inflammation and Rare and Neuro Disease therapeutic areas.

15:35 – 15:45

Afternoon refreshments

15:45 – 16:45

Strategies and considerations of discovering antibodies against novel targets

What is known about the target’s biology? How should the antibody impact this biology?
What is your draft target-candidate-profile? What is your final antibody format?
What reagents and comparator antibodies do you have at your disposal to characterize newly discovered antibodies?
What antibody discovery technologies should you deploy for your novel target? Should you consider an immunization or display-based antibody discovery platform? How will you screen for your desired candidate antibodies?

Jan-Willem Theunissen

Director Biology, Mersana Therapeutics

Jan received his PhD from Weill Cornell and completed post-doctoral training at Genentech. He has over a decade of experience in cancer target discovery and biologics drug development. Jan started his industry career at Amgen, where he led surface antigen discovery and validation efforts for gastric cancer. Subsequently, he managed an antibody discovery team at Igenica Biotherapeutics, a company that focused on mass spectrometry-based antigen discovery for cancer immunotherapy. At Iconic Therapeutics, his team discovered and developed Tissue Factor-targeted biologics. Prior to joining Mersana Therapeutics, Jan had a senior role on the biologics team at Gilead Sciences, supporting protein therapeutics discovery across multiple disease indications. In his current role at Mersana, he is actively engaged in antibody drug conjugate discovery for oncology indications with high unmet need.

17:45 – 18:45

Evening Drinks Reception

Lead Identification & Optimization

Time

Titles and Bullets

Facilitator

8:00 – 8:30

Registration

8:30 – 9:00

Opening Address & Keynote Presentation
Evolution of In Vivo Platforms for Antibody Drug Discovery

Jane Seagal

Vice President, Antibody Discovery, AlivaMab

9:05 – 10:05

Challenging targets: Opportunity, vs effort, vs risk: General strategies vs custom approaches: In the end you want the best antibody, no matter what

What are the current advantages in obtaining diversified binders to multi-transmembrane targets (e.g. GPCR)
What are ways to do functional screening at hit generation stage?
What are the recent developments on AI based Ab discovery?
What are the lead optimization strategy for agonistic antibodies?

Qian Zhang

Senior Director, Lead Evaluation and Protein Science, HiFiBiO Therapeutics

Qian Zhang is the Senior Director, Global Head of Antibody Discovery and Optimization at HiFiBiO Therapeutics. He is a biochemist by training with 10 years of industry experience and expertise in structural biology, analytical chemistry and antibody engineering. Before joining HiFiBiO, Qian worked at Regeneron as a Staff Scientist focusing on novel protein biochemistry and mass spectrometry-based methods for antibody characterization, supporting various mono and bi-specific antibody and ADC programs. Qian holds a B.S. in Biology from the University of Science & Technology of China, a M.S. in Biochemistry from Georgia Institute of Technology, and a Ph.D. in Analytical Chemistry.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

The fastest and most effective way from discovery to development

Immune repertoire recovery: advantages and limitations of current technologies
Narrowing down potential candidates: how early is too early to screen for developability?
Advanced modalities and formats: how discovery can address key gaps?

Jane Seagal

Vice President, Antibody Discovery, AlivaMab

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation
Wrangling diverse OmniAb antibody repertoires with OmniDeep

Bob Chen

Senior Director, Systems Engineering, OmniAb

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:00 – 15:30

Poster Session

Pioneer: a novel biotherapeutic antibody discovery platform

The Pioneer Antibody Discovery Platform is Bio-Rad’s new service for biotherapeutic discovery. The Pioneer Platform comprises a new antibody phage display library engineered to have optimal properties for the selection of therapeutic candidates, including the reduction of CDR-located posttranslational modification sites for improved developability. With 92% of the clones (VH and VL combined) encoding functional antibodies, the Pioneer Antibody Library encodes 2.25×1011 unique antibodies. Pioneer takes advantage of SpyDisplay, a novel selection system based on SpyTag technology. Herein, we demonstrate that the Pioneer Platform delivers diverse high-affinity antibody lead candidates. Using anti-TIGIT antibodies, we show that the performance of our lead candidates is comparable with antibodies undergoing clinical trials.

Paul Royle

Technical Sales Manager, Custom Antibodies, Bio-Rad Laboratories

Paul Royle is the technical sales manager for Bio-Rad’s Custom Antibody Service (HuCAL®) and has been with Bio-Rad’s antibody division for over 9 years. Prior to this he worked in an immunology diagnostics company for almost 7 years. Paul holds a degree and PhD from the University of Nottingham (UK), and has post-doctoral research experience from the University of Warwick (UK).

15:35 – 16:35

One size doesn’t fit all: Key considerations for successful therapeutic antibody discovery for various modalities and indications

How to incorporate biology considerations into antibody discovery approaches?
How much data and effort do we need to put to make decisions either to move to lead OP or to terminate the program?
How can we accelerate timeline without compromising quality?”

Sarav Narayanan

Principal Scientist, Takeda

Sarav Narayanan is currently leading immunology and Immuno-oncology programs at Takeda’s Global Biologics, supporting triage strategy, lead identification and optimization. His expertise in protein analytics and antibody discovery combined with years of experience in supporting immunology research impacts Takeda’s drug discovery programs. Prior to joining Takeda, Sarav was a scientist at biologics drug discovery group at Biogen and led Immunology research programs. He successfully transitioned molecules to development, out- licensed to partners and to clinic. Sarav Narayanan received PhD in biochemistry from TU-Munich, Germany and completed his postdoctoral research in the field of membrane protein biochemistry as a Harvard-Lefler ostdoctoral fellow at Harvard Medical School.

16:35 – 16:45

Afternoon refreshments

16:45 – 17:45

Can NGS data from antibody screening be used to identify rare and high-affinity clones using machine learning?

Standard antibody screening workflows depend on Sanger and ELISA to identify initial hits.
Adding NGS to the workflow allows tracking of enrichment and identifying clones not obtained from random hit picking.
With recent advances in deep-learning, can NGS data be leveraged to generate high-affinity and rare clones to maximize sequence diversity at the lead ID stage?

Sunandan Banerjee

Associate Principal Scientist, Merck

Sunandan Banerjee is an Associate Principal Scientist at Merck, Boston. He leads phage display efforts at Merck with a focus on single-domain scaffolds. Sunandan holds a PhD in protein design from University of Vermont and trained in synthetic antibody technologies at University of Toronto. Prior to Merck, Sunandan worked in antibody discovery and engineering at Lake Pharma and Soteria Biotherapeutics. His current interests lie in optimizing synthetic CDR repertoires and merging discovery and data for optimal lead discovery.

17:45 – 18:45

Evening Drinks Reception

Formats & Scaffolds

Time

Titles and Bullets

Facilitator

08:00 – 08:30

Registration

08:30 – 09:00

Opening Address & Keynote Presentation
Evolution of In Vivo Platforms for Antibody Drug Discovery

Jane Seagal

Vice President, Antibody Discovery, Alivamab

09:05 – 10:05

Fc engineering for improved antibody druggability

Fc engineering and POC in mice humanized for Fc Receptors
Fc and glycosylation
Fc engineering and manufacturability

Joel Cohen-Solal

Principal Research Scientist, AbbVie

Joel did his PhD in the Lab of Wolf Herve Fridman in Paris on FcgR glycosylation and function and then join the lab of Betty Diamond in Columbia University in NYC where he worked on the balance between tolerance and autoimmunity. He moved to AbbVie in 2015 where he is leading the Fc Biology team.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Lead Identification & Optimization topic
The Specifica Generation 3 Antibody Discovery Platform

Drug-like antibodies directly from an in vitro platform – no animals needed
All libraries based on well behaved clinical scaffolds
20% antibodies subnanomolar; 80% antibodies no biophysical liabilities; 10-1000 different clusters per campaign
Full platform transfer as an asset purchase or discovery/optimization campaigns at Specifica (scFv, Fab or VHH)
Platform simultaneously affinity matures (≤400x improved affinity) and improves developability
No milestones or royalties

Andrew Bradbury

Chief Scientific Officer, Specifica

Andrew Bradbury is CSO of Specifica. He trained in medicine at the universities of Oxford and London and received his PhD from the university of Cambridge mentored by Nobel Laureate, Cesar Milstein. He has worked in phage/yeast display, library generation and antibody engineering for >35 years. He was cofounder and first president of The Antibody Society and has published >170 peer-reviewed articles, including a highly cited Nature commentary calling for the use of recombinant antibodies as research reagents to improve reproducibility. His mission is to enable companies developing therapeutic antibodies with the world’s best in vitro antibody discovery platform.

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation
Wrangling diverse OmniAb antibody repertoires with OmniDeep

Bob Chen

Senior Director, Systems Engineering, OmniAb

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:35 – 16:35

Considerations for CAR-T/ CAR-NK Cell binder format designs during screening and selections

What are the costs and benefits of common binding scaffolds including formats like Fab, scFv, VHH, TCR, and synthetic scaffolds? Are there preferences in the field?
Do classical Drug-Like Properties for recombinant proteins apply when selecting binders for CARs? Are there assays which can help predict success in the CAR format?
At what point in the screening process should the binder be engineered into its final format? When should other components of the receptor be finalized? Is there an assay to predict what binder might be better suited for an “armored” CAR or NK Cell?
Are there desired binding kinetics? Does affinity, avidity, or specific on/off rates correlate with better performance as a CAR?

Shawn Jennings

Senior Scientist, Beam Therapeutics

Shawn currently works at Beam Therapeutics where he leverages his Biotherapeutics knowledge synergistically with In-Vivo editing of human primary cells to cure diseases. He has over 10 years of experience in Biotherapeutic generation and engineering while functioning in different roles from antibody generation lead to project team leader. Shawn is a co-author on several patents with topics including hybridoma techniques, immunotherapies, and cell therapies including CAR-T and CAR-NK cells. Several biotherapeutics which he worked on have entered clinical studies and the cell therapies are positioned to enter the clinic in the near future. Shawn received his B.S. in Biology at Fairfield University and a M.S. in Molecular and Cell Biology at Brandies University.

16:35 – 16:45

Afternoon Refreshments

16:45 – 17:45

Current challenges in design of bispecific/ chimeric antigen receptors for solid tumours

What are the best designs to overcome a suppressive tumor microenvironment?
Designing around tumor accessibility and selectivity depending on target expression.
What strategies can be employed for each modality to increase efficacy, therapeutic index, safety and durability of response

Medha Tomlinson

Director, Global Biologics Research, Takeda Pharmaceuticals

Medha Tomlinson is currently a director at Takeda and leads biologics for cell engager and cell therapy programs. She joined Takeda in 2019 to help build and advance biologics modalities at Takeda and heads the therapeutic generation and screening team with Biologics. Prior to Takeda, she was at Abbvie for several years where she headed the purification and characterization teams for various programs and helped advance several oncology and immunology therapeutics in the clinic. She completed her Ph.D. at the University of Cincinnati and her postdoctoral work at University of California Riverside.

17:45 – 18:45

Evening Drinks Reception

Bi/Multi-Specifics

Time

Titles and Bullets

Facilitator

08:00 – 08:30

Registration

08:30 – 09:00

Opening Address & Keynote Presentation
Evolution of In Vivo Platforms for Antibody Drug Discovery

Jane Seagal

Vice President, Antibody Discovery, Alivamab

09:05 – 10:05

Bi/tri-specific strategies for overcoming cell engager toxicity

Identifying tumor-specific antigens, is it clean enough?
Ways to optimize your cell engagers: format, binding affinity and other potency properties
How about conditionally activated cell engagers (pH, tumor-expressed proteases, metabolites, co-expression of two or more TAAs)?
TCEs vs NKCEs

Hao Chen

Director of Protein Science, ModeX Therapeutics

Dr. Hao Chen is the Director of Protein Science, Biologics Discovery and Development at ModeX Therapeutics, a biotech startup dedicated to the concept of modulating multiple disease targets with innovative multi-targeting strategies. Hao joined ModeX in early 2022 to help build their antibody production and characterization platforms, with an emphasis on screening and optimizing the biochemical and biophysical properties of multispecific antibodies. Prior to ModeX, Hao was a group leader at Biologics department at Amgen and subsequently Sanofi. He obtained his Ph.D from Rutgers University/HHMI and completed his postdoctoral training at Whitehead Institute, MIT.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

11:20 – 12:20

Proteomics Enhanced Antibody Discovery: quicker projects with polyclonal antibody sequencing

When do you consider outside technologies for antibody generation?
Have you considered camelid antibodies which were not derived from display libraries?
Where do you seek out prospective bi/multispecific antibodies after in-house efforts?
Do you create biologically specific bi/multi-specific arms?

Anthony Stajduhar

Director of Business Development, Rapid Novor

Anthony has been heading the business development at Rapid Novor for nearly 6 years, merging his previous 8 years of experience in the business roles with a strong passion for biomedical research, stemming from his training in biomedical engineering. His current efforts are focused on the growth of the REpAb™, HDX-MS epitope mapping, and SPR Kinetic analysis solutions with pharmaceutical and biotech companies globally. His partnerships are focused on using REpAb in patients or animal models to sequence monoclonal antibodies from polyclonal sera, as well as immune system profiling using NovorIg, the team’s NGS based analysis to monitor the relative quantity of specific antibodies over time. Anthony’s a hobby farmer and an ongoing researcher of biotech business in his spare time.

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation
Wrangling diverse OmniAb antibody repertoires with OmniDeep

Bob Chen

Senior Director, Systems Engineering, OmniAb

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:00 – 15:30

Poster Session
Lead Identification & Optimization Topic
A case study on flexibility: Evitria’s bespoke solutions for lead selection and optimization

High quality research. Fast timelines. And within budget. As a scientist or research leader, you’re often only allowed two out of these three options.

But what if you could have all three? Utilizing evitria’s bespoke workflow solutions supports preclinical research of any stage, with any format, and at any scale greater than 1-mg. Reliable production with a great support team allows evitria to tailor each project and ensure that your material reaches you the way you need it and when you need it. With over 120,000 successful antibody production runs, evitria’s materials have helped teams to enter clinical trials and successfully commercialize. Let our 13-year history of focused services help your research to advance as well.

Richard Park

Global Head, Client Relations, Evitria

Richard Park leads the Client Relations and Business Development team at evitria AG, a company whose mission is to provide the highest quality, research-grade antibody and protein reagents to support antibody therapeutic developers. Richard joined evitria in January 2020 and came from a diagnostic sales background at QIAGEN and in diagnostic development research in conjunction with Brown University and Perkin Elmer. Richard holds a Bachelor of Science in Biomedical Engineering from Brown University and a Bachelor of Arts in French Studies also from Brown University.

16:35 – 16:45

Afternoon Refreshments

17:45 – 18:45

Evening Drinks Reception

Emerging Technologies

Time

Titles and Bullets

Facilitator

08:00 – 08:30

Registration

08:30 – 09:00

Opening Address & Keynote Presentation
Evolution of In Vivo Platforms for Antibody Drug Discovery

Jane Seagal

Vice President, Antibody Discovery, Alivamab

09:05 – 10:05

What is the optimum human CDR-H3 repertoire for antibody discovery?

What are the historical methods for generating CDRH3 diversity in naïve libraries?
What are some of the more recent improvements?
Where do we find the biggest improvement in outcome compared with effort?
Is broad CDRH3 diversity necessary? What are advantages of CDRH3 vs Combinatorial diversity?
Human vs. Synthetic, which is better?

Jonathan Davis

Vice President, Strategy and Innvoavtion, Invenra

Jonathan Davis is Vice President of Innovation and Strategy at Invenra, where he brings over 20 years of experience in industry, focused on innovative protein and antibody engineering, bispecific and multispecific antibody platform development, and drug discovery in a wide range of therapeutic areas. Prior to joining Invenra, Dr. Davis has held positions at Bristol-Myers Squibb, where he worked on all aspects of biologic drug design, including successfully designing a trispecific HIV biotherapeutic, and EMD Serono, where he developed novel biologic drug platforms. Prior to his industry jobs, Dr. Davis was a post-doctoral fellow at Harvard Medical School, and earned a Ph.D. in Biophysics from Univ. of Cal. San Francisco and a bachelor’s degrees in music and cello from Reed College and San Francisco Conservatory of Music.

10:10 – 10:40

1-2-1 Meetings/Networking Break

10:40 – 11:10

1-2-1 Meetings/Networking Break

11:10 – 11:20

Morning Refreshments

12:20 – 13:20

Networking Lunch

13:20 – 13:50

Spotlight Presentation
Wrangling diverse OmniAb antibody repertoires with OmniDeep

Bob Chen

Senior Director, Systems Engineering, OmniAb

13:55 – 14:25

1-2-1 Meetings/Networking Break

14:25 – 14:55

1-2-1 Meetings/Networking Break

15:00 – 15:30

Poster Session
SMART Chromatography™ – linearly scalable one-step clarification and purificationin packed bed chromatography

SMART Chromatography™ combines clarification and purification into a single step, reducing losses of valuable product from the bioreactor, increasing overall productivity and reducing total process costs. The undiluted cell broth is applied directly to the column – cells pass through the packed chromatography bed and antibody selectively binds to the solid phase (Protein A, etc.). Once unbound materials have been washed away, the concentrate, purified antibody is eluted. The technology is linearly scalable from R&D to manufacturing. It has been used with a wide range of antibody producing cell lines (CHO, HEK, etc.), including the Dyadic C1 filamentous fungi for human IgG4.

Alistair Hurst

General Manager (USA) & Business Development Director (Global), EMP Biotech

Alistair Hurst is the General Manager at emp BIOTECH’s subsidiary in the USA. For more than 30 years he has been active in the downstream processing sector and has developed a number of purification technologies to improve purification performance.

15:35 – 16:35

Mining antibody repertoire from tumor patients

How specific is patient immune response?
Unbiased or targeted: how screening paradigm affects the outcome.
Future today: how in silico methods accelerate repertoire mining.
Combination of in silico and wet lab methods

Pavel Nikitin

Senior Director Antibody Engineering, Immunome

Pavel A. Nikitin, PhD, is an antibody engineer with 10+ years of industry experience in developing biologics for the treatment of cancer, inflammatory, and infectious diseases. Pavel heads Antibody Engineering group at Immunome, where he developed several therapeutics, including a novel immune modulator IMM-ONC-01 intended for treatment of solid tumors, and a neutralizing anti-viral cocktail IMM-BCP-01. Prior to joining Immunome, Pavel was a Senior Scientist at True North Therapeutics, a startup in SF Bay Area that developed a monoclonal antibody Sutimlimab (commercialized as Enjaymo by Sanofi). Pavel received his PhD in Molecular Genetics and Microbiology from Duke University.

16:35 – 16:45

Afternoon Refreshments

17:45 – 18:45

Evening Drinks Reception

ANTIBODY THERAPEUTICS XCHANGE
EAST COAST 2023
Boston
May 22, 2023

SNAPSHOTS OF DISCUSSION TOPICS

Full Xchange Agenda

Target Selection

Lead Identification & Optimization

Formats & Scaffolds

Bi/Multi-Specifics

Emerging Technologies

Partners

© Copyright 2023 by Weblify & Webtec

ANTIBODY THERAPEUTICS XCHANGE EAST COAST 2023 Boston May 22, 2023

SNAPSHOTS OF DISCUSSION TOPICS

Full Xchange Agenda

Target Selection

Lead Identification & Optimization

Formats & Scaffolds

Bi/Multi-Specifics

Emerging Technologies

Partners

ANTIBODY THERAPEUTICS XCHANGE
EAST COAST 2023
Boston
May 22, 2023